| Dr Jeffrey W Watkins, MD | |
|
350 Heritage Way Ste 2100, Kalispell, MT 59901-3167 | |
| (406) 257-8992 | |
| (406) 275-8996 |
| Full Name | Dr Jeffrey W Watkins |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 350 Heritage Way Ste 2100, Kalispell, Montana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053349860 | NPI | - | NPPES |
| Entity Name | Sanford Clinic North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548532468 PECOS PAC ID: 4284546151 Enrollment ID: O20031209000264 |
News Archive
Small pieces of nucleic acid, known as siRNAs (short interfering RNAs), can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials. Now, three new reports highlight the progress that researchers are making in developing broadly applicable, nanoparticle-enabled siRNA anticancer therapeutics.
In cases of severe ocular trauma involving the cornea, wound healing occurs following intervention, but at the cost of opaque scar tissue formation and damaged vision. Recent research has shown that mesenchymal stem cells (MSCs) — which can differentiate into a variety of cells, including bone, cartilage, muscle and fat cells — are capable of returning clarity to scarred corneas; however, the mechanisms by which this happens remained a mystery — until now.
When dining out, 65 percent of Americans prefer to see nutritional information on a restaurant menu over calories alone. As several cities around the country adapt to menu-labeling mandates that require restaurants to post calorie-counts on their menu, it is yet to be determined if it will have the desired impact on consumer behavior and therefore overall public health.
A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.
› Verified 2 days ago
| Entity Name | Sanford Health Network North |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1043218753 PECOS PAC ID: 8022206663 Enrollment ID: O20180222001872 |
News Archive
Small pieces of nucleic acid, known as siRNAs (short interfering RNAs), can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials. Now, three new reports highlight the progress that researchers are making in developing broadly applicable, nanoparticle-enabled siRNA anticancer therapeutics.
In cases of severe ocular trauma involving the cornea, wound healing occurs following intervention, but at the cost of opaque scar tissue formation and damaged vision. Recent research has shown that mesenchymal stem cells (MSCs) — which can differentiate into a variety of cells, including bone, cartilage, muscle and fat cells — are capable of returning clarity to scarred corneas; however, the mechanisms by which this happens remained a mystery — until now.
When dining out, 65 percent of Americans prefer to see nutritional information on a restaurant menu over calories alone. As several cities around the country adapt to menu-labeling mandates that require restaurants to post calorie-counts on their menu, it is yet to be determined if it will have the desired impact on consumer behavior and therefore overall public health.
A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey W Watkins, MD 1300 Anne St Nw, Bemidji, MN 56601-5103 Ph: (218) 333-5000 | Dr Jeffrey W Watkins, MD 350 Heritage Way Ste 2100, Kalispell, MT 59901-3167 Ph: (406) 257-8992 |
News Archive
Small pieces of nucleic acid, known as siRNAs (short interfering RNAs), can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials. Now, three new reports highlight the progress that researchers are making in developing broadly applicable, nanoparticle-enabled siRNA anticancer therapeutics.
In cases of severe ocular trauma involving the cornea, wound healing occurs following intervention, but at the cost of opaque scar tissue formation and damaged vision. Recent research has shown that mesenchymal stem cells (MSCs) — which can differentiate into a variety of cells, including bone, cartilage, muscle and fat cells — are capable of returning clarity to scarred corneas; however, the mechanisms by which this happens remained a mystery — until now.
When dining out, 65 percent of Americans prefer to see nutritional information on a restaurant menu over calories alone. As several cities around the country adapt to menu-labeling mandates that require restaurants to post calorie-counts on their menu, it is yet to be determined if it will have the desired impact on consumer behavior and therefore overall public health.
A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.
› Verified 2 days ago
Dr. Tobin James Hoppes, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 75 Claremont St Ste H, Kalispell, MT 59901 Phone: 406-752-7406 Fax: 406-752-7544 | |
Marise K Johnson, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1280 Burns Way, Kalispell, MT 59901 Phone: 406-755-5266 Fax: 406-755-0228 | |
Kerry J Eby, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 310 Sunnyview Ln, Kalispell, MT 59901 Phone: 406-751-6725 | |
Torbjorn Ingvar Joreteg, MD PHD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 160 Heritage Way, Kalispell, MT 59901 Phone: 406-755-7785 Fax: 406-755-7857 | |
Nathaniel Lyle Hall, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 350 Heritage Way, Suite 2100, Kalispell, MT 59901 Phone: 406-257-8992 Fax: 406-751-4161 | |
Anna Rose Robbins, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 310 Sunnyview Ln, Northwest Hospitalists, Kalispell, MT 59901 Phone: 406-751-5310 Fax: 406-751-5769 |